United Therapeutics (UTHR) CEO Rothblatt Sells 9,500 Shares

Rothblatt's Recent Sale

Martine Rothblatt, the Chairperson and CEO of United Therapeutics Corporation (NasdaqGS: UTHR), sold 9,500 shares on June 26, 2026. At the time of the sale, the stock was priced at $538.40, bringing the total value of the transaction to approximately $5.1 million. This sale follows a series of transactions by Rothblatt, reflecting her active involvement in the company's stock.

Context of the Sale

Rothblatt's recent sale comes after she purchased 9,500 shares at $135.42 each just a day earlier, on June 25, 2026, for a total of about $1.29 million. This pattern of buying and selling shares indicates her ongoing engagement with the company's stock performance. On June 22, she also bought 9,500 shares at $138.67, further underscoring her active trading strategy.

Institutional Activity

No other funds reported changes in their positions for United Therapeutics during this period. This lack of peer activity might suggest a cautious approach among institutional investors regarding the stock, especially in light of Rothblatt's recent trading activity.

How United Therapeutics Corporation Stock Has Traded

United Therapeutics shares have been trading well above their 50-day moving average of $515.58 and are currently positioned between a 52-week low of $409.07 and a high of $609.35. As of the last close, the stock was at $538.40, indicating a positive trend compared to recent weeks. This performance may be a factor in Rothblatt's decision to manage her holdings actively.

Recent Earnings

In its last earnings report, United Therapeutics reported revenue of approximately $3.15 billion, with a net margin of 41.6%. The company is set to announce its next earnings on October 28, 2026. This upcoming report could provide further insights into its financial health and impact investor sentiment.

Analysts Set New Price Targets

Analysts have been generally positive about United Therapeutics. On October 8, 2026, RBC Capital maintained an "Outperform" rating with a target price of $708. Earlier in October, Morgan Stanley also maintained an "Equal-Weight" rating with a target of $566. The consensus from 12 analysts suggests a mean price target of $664.33, reflecting confidence in the company's future performance.

About United Therapeutics

United Therapeutics Corporation focuses on developing treatments for chronic and life-threatening diseases, particularly in the pulmonary arterial hypertension space. Its innovative products aim to meet significant medical needs, which is vital for its market positioning.

What's Ahead for United Therapeutics Corporation

Investors will be watching for updates from United Therapeutics, particularly the next earnings report on October 28. As a reminder, insider transactions like Rothblatt's reflect past activities and may not indicate current positions. Further updates on analyst ratings and any new filings will also be of interest as they may influence stock performance.